Cargando…

OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment

BACKGROUND: Up to now, only few data are available regarding the efficacy of anti-SARS-CoV-2 vaccines in patients with plasma cell neoplasia. This ongoing observational study aimed to describe the level of post-vaccination anti-SARS-CoV-2-antibodies depending on B lymphocyte count, current therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghandili, Susanne, Schönlein, Martin, Lütgehetmann, Marc, Wiesch, Julian Schulze zur, Becher, Heiko, Bokemeyer, Carsten, Sinn, Marianne, Weisel, Katja, Leypoldt, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580176/ http://dx.doi.org/10.1016/S2152-2650(21)02123-6

Ejemplares similares

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021)

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
por: Ghandili, Susanne, et al.
Publicado: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study
por: Schönlein, Martin, et al.
Publicado: (2022)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis
por: Modemann, Franziska, et al.
Publicado: (2022)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Expanding anti-CD38 immunotherapy for lymphoid malignancies
por: Wang, Xu, et al.
Publicado: (2022)

Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML
por: Brauneck, F., et al.
Publicado: (2021)

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
por: Leleu, Xavier, et al.
Publicado: (2022)

Downregulation of the 5’-ectonucleotidase CD73 of CD8+ CTL of HIV infected patients correlates with immune activation and diminished IL-2 production
por: Toth, I, et al.
Publicado: (2012)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Comprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes
por: Heide, Janna, et al.
Publicado: (2019)

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage
por: Muscate, Franziska, et al.
Publicado: (2018)

Transfusion management for patients taking an anti-CD38 monoclonal antibody
por: Bub, Carolina Bonet, et al.
Publicado: (2018)

Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms
por: Isabelle, Colleen, et al.
Publicado: (2023)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

A Comparative Outcome Analysis of COVID-19 and Influenza Infection in Patients with Hematological Malignancies
por: Ghandili, Susanne, et al.
Publicado: (2021)

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
por: Modemann, Franziska, et al.
Publicado: (2022)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
por: Xiong, Hui, et al.
Publicado: (2021)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018)

Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
por: Benfaremo, Devis, et al.
Publicado: (2019)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

The Clinical Perspective on Hepatitis E
por: Horvatits, Thomas, et al.
Publicado: (2019)

Clinical features of hepatitis E infections in patients with hematologic disorders
por: Ghandili, Susanne, et al.
Publicado: (2022)

High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4(+) T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19
por: Cords, Leon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iagggqffqpmqu74kktp3evr59k